Next Chip Squeeze in Oxygen? - Disruption Risk Intelligence, Edition 4
Medical grade oxygen is a critical to essential therapeutic care. Biomedical equipment for oxygen treatment is highly dependent on components that are other industries use. This Edition discusses how these other sectors have and could potentially impact access to oxygen.
The Next Chip Squeeze in Oxygen?
Disruption Risk Intelligence — Edition 4
7 September 2026
Verolyx is an independent publication and the founding proof-of-concept for the planned Verolyx Verein.
| 1 | AT A GLANCE | MODERATE |
This is a forward-looking risk note: a chip-allocation squeeze is already documented and current across general medical device manufacturing, and this edition asks whether the same mechanism could next reach oxygen concentrators and PSA (pressure swing adsorption) plants, equipment sitting on top of an already severe global oxygen access gap. The general medtech impact is real and current as AdvaMed's August 2026 survey found 75% of member companies reporting memory chip-related constraints and 88% reporting price increases. However, the extension specifically to oxygen equipment is not yet documented in 2026 sources, though it has happened once before, in the 2022–23 chip cycle. See Sections 3 and 4.
| DEMAND / COMPETITIVE DRIVER | AI/data-center memory demand (documented, current) alongside a separate, longer-running automotive/EV and industrial squeeze on legacy-node microcontrollers and power devices is the component category more relevant to oxygen equipment. |
| What is happening | AdvaMed (17 Aug 2026): 75% of respondent medtech firms report memory chip-related constraints, 88% report price increases, 63% report supplier allocation challenges. ResMed's FY2026 investor materials discuss supply chain and circuit-board assembly priorities; the specific semiconductor shortage wording should be tied to the relevant earnings call transcript. |
| Why it matters beyond ventilators | Imaging, patient monitors, infusion pumps, ventilators, and surgical robotics all draw on the same constrained memory components; a separate potential pathway involves mature-node microcontrollers, power semiconductors, motor control components, and industrial electronics. This is technically plausible for oxygen concentrators and PSA plants, but the present evidence does not establish a 2026 supply impact on those products. |
| What to watch next | Whether the FDA's medical device shortage list adds an oxygen concentrator or PSA product; whether a named manufacturer confirms a component-cost link; and whether the WHO/PAHO respiratory watch list, currently low-signal, changes. |
| 2 | TYPE OF RISK | Demand Trigger |
The current chip squeeze is a Demand Trigger: growth in AI/data-center capacity is reallocating global memory (DRAM/NAND) production toward that buyer, at the expense of other purchasers including medical device makers — a demand shift, not an external shock or a natural-disaster-driven scarcity.
A distinct but related Competitive/Structural layer covers the component category more relevant to oxygen equipment specifically: legacy-node microcontrollers and power semiconductors used in industrial controls, compressor drives, and motor controllers — concentrated in automotive, EV, and industrial buyers, not the AI/memory demand driving the first pathway.
| 3 | Market Evidence | Value Chain Overview |
The chip market connects global fabs and foundries to two device categories with different exposure: general medtech (monitors, imaging, ventilators, infusion pumps — running on memory-heavy electronics) and simpler industrial-control equipment such as oxygen concentrators and PSA plants (running on legacy-node microcontrollers and power devices). This section separates what is directly documented from what is structurally plausible but not yet evidenced.
|
1. CROSS-SECTOR DEMAND LAYER
Assessment: Only the direct general-medtech pathway is currently backed by named company and trade-association disclosure. The oxygen-equipment-specific pathway is structurally plausible and worth tracking. |
2. VALUE CHAIN VULNERABILITY LAYER
Assessment: The baseline access gap and the documented 2026 component-shortage category are both real; the link between them for oxygen equipment specifically remains the open question this edition flags. |
|
3. TRIGGER LAYER
Assessment: Two distinct triggers are operating concurrently on different component categories; conflating them into a single “AI chip demand” story would overstate the oxygen-equipment link. |
4. COMPETITIVE / STRUCTURAL LAYER
Assessment: A repeat of this same over-/under-correction pattern is the structural risk this edition flags, not a prediction of a specific 2026 shortage date. |
| 4 | COMPOSITE INSTABILITY SCORING |
Each tracked event or material receives a composite instability score built from five independently scored dimensions. The composite is not a precise probability estimate, but a structured, comparable severity read, intended to make several concurrent signals easy to compare at a glance.
| Dimension | Severity | Trend |
|
Signal Trajectory:
Is the underlying signal accelerating, steady, or resolving?
(Pulls from Trigger Layer)
|
LOWMEDIUMHIGH
High score signifies an escalating, unresolved trigger. |
General medtech chip impact is current and documented; AdvaMed's survey indicates respondents expect constraints to persist. |
|
Concentration Risk:
How few independent points of failure exist, i.e. single country, single company, single product, etc.
(Pulls from Value Chain Vulnerability)
|
LOWMEDIUMHIGH
High score signifies lack of diversification. |
Chip supply is distributed across many fabs — but legacy-node/automotive-grade capacity is concentrated among a small number of named suppliers, the more relevant reference class here. |
|
Substitutability:
Does an alternative realistically exist? Is the alternative constrained?
(Pulls from Value Chain Vulnerability)
|
LOWMEDIUMHIGH
High score signifies constrained or unavailable substitutes. |
General medtech firms report actively pursuing alternate sourcing and inventory (AdvaMed). No oxygen-equipment-specific substitution evidence unknown. |
|
Time to Impact:
How much lead-time buffer exists before the disruption reaches an end user?
(Pulls from Trigger Layer and Value Chain Vulnerability)
|
LONG TERMINTERMEDIATEIMMEDIATE
Immediate signifies minimal buffer. |
General medtech impact is already realized. An oxygen-equipment-specific impact, if the 2021–23 pattern repeats, would plausibly lag by a similar multi-quarter window. |
|
Precedent Frequency:
Has this pattern occurred before, and how often? Is it historically a one-off event versus a recurring event, market weakness?
(Pulls from Trigger Layer's historical record)
|
LOWMEDIUMHIGH
High signifies recurring precedents. |
This would be the second chip-driven cycle to reach this product category in five years; FDA's own discontinuance record documents the first one. A potentially recurring pattern. |
Composite is analyst-assigned against the methodology's rubric, using public data. Not an automated statistical model.
| 5 | FINAL ASSESSMENT | MODERATE |
This MODERATE classification reflects a deliberate separation of two distinct questions: whether general medtech is affected by chip constraints today, and whether oxygen-equipment supply specifically is affected today. The first is documented and current. The second has no confirmed 2026 instance, though the component-category overlap and a direct 2022–23 precedent both support tracking it closely. Surveillance context: the public disease-outbreak records (WHO Disease Outbreak News, PAHO alerts) reviewed did not identify a current mass-casualty respiratory event, but an elevated background of pandemic-potential pathogen activity, including ongoing MERS-CoV monitoring, avian influenza spillovers through 2025, and a contained Andes hantavirus cluster (13 cases, 3 deaths, closed 2 Jul 2026), that would sharply raise the stakes of any oxygen-equipment constraint should it escalate.
- General medtech chip impact is real, current, and documented by primary sources: AdvaMed's August 2026 survey, Becker's/NYT reporting, and ResMed's own FY2026 earnings disclosures.
- The oxygen-equipment-specific extension is not yet evidenced for 2026, but it has a direct, documented 2022–23 precedent (FDA's CAW-coded portable oxygen generator discontinuances) and would land on a baseline access gap (the Lancet Global Health Commission's estimated 5+ billion people without reliable oxygen access) with near-zero slack.
- The two chip pathways are mechanistically distinct: AI/data-center demand for memory is documented and current for higher-end devices; automotive/EV and industrial demand for legacy-node microcontrollers is the more plausible pathway for oxygen equipment specifically.
- Recommended watch items for the future editions: any FDA shortage-list addition for oxygen concentrators or PSA plants; primary confirmation of a component-cost link at a named oxygen-equipment manufacturer; and any change in the currently low-signal WHO/PAHO respiratory watch list.
| A | ANNEX | Notes |
- On unverified market figures: several granular memory-market statistics circulating in trade and analyst commentary this period — specific DRAM undersupply percentages, spot-price moves, and named-bank forecasts — were not independently confirmed against primary sources this edition and are excluded from the evidentiary base in Section 3, flagged here for confirmation in the next research pass.
- On two citations checked and not confirmed: a claimed WHO Mpox Rapid Risk Assessment “v.7” (24 Aug 2026) could not be located; the latest confirmed version is v.6 (Feb 2026), used instead. A claimed WHO Global Respiratory Virus Activity Weekly Update “N°593” (2 Sept 2026) could not be located; the latest confirmed report is N°592 (week 33, ending 16 Aug 2026).
- On source hierarchy: FDA's own shortage/discontinuance lists and named-company earnings-call disclosures (ResMed) are treated as primary; the AdvaMed/Deloitte survey as primary trade-association research; market-research-firm commentary as secondary/industry-analyst tier.
- WHO: All disease-surveillance citations here are drawn from WHO's public-facing Disease Outbreak News and Rapid Risk Assessments, and PAHO's public epidemiological updates.
| B | ANNEX | Sources |
AdvaMed / Deloitte, “Memory Chip Shortages: Implications for Medtech Innovation and Patient Care” (17 Aug 2026); Becker's Hospital Review, “AI chip shortage threatens medical device supply” (Aug 2026); ResMed Inc., Q3 FY2026 and Q4 FY2026 earnings call transcripts (Apr, Aug 2026); Microchip USA, “Electronic Component Shortage 2026: Vishay, Onsemi & Infineon Risks” (27 Feb 2026); AdvaMed, submission to U.S. Department of Commerce on semiconductor supply chain risk. FDA, Medical Device Shortages List (updated through Jun 2026); FDA, Device Discontinuance List / COVID-19 medical device shortage updates (2022–23; portable oxygen generators, product code CAW); Health Canada, Medical Device Shortages database (Invacare portable oxygen concentrator discontinuations). Lancet Global Health Commission on Medical Oxygen Security (2024–25); The Global Fund, 39-country facility-level oxygen access assessment; Coherent Market Insights, “Oxygen Concentrators Market Share & Opportunities 2026–2033”; 24 Market Reports, “Global Stationary Home Oxygen Concentrator Market, Global Outlook and Forecast 2026–2034.” WHO, Disease Outbreak News 2026-DON611, “Hantavirus outbreak linked to cruise ship travel” (2 Jul 2026); PAHO, “Avian influenza in the Americas: animal outbreaks decline, but PAHO calls for continued vigilance” (27 Aug 2026); WHO, Rapid Risk Assessment — Mpox, Global v.6 (Feb 2026); WHO, Global Respiratory Virus Activity: Weekly Update N°592 (week 33, ending 16 Aug 2026); PAHO, Epidemiological Alert, “Simultaneous circulation of seasonal influenza and RSV” (9 Jan 2026). Contemporaneous reporting on Canada's ventilator stockpile and 2024 component scrap sales (primary audit/press citations recommended before external publication).
| C | ANNEX | Background (Summarized) |
Why oxygen and ventilators are treated as separate problems
Early COVID-19 demand forecasting prioritized ventilator production in the first couple of months incorrectly; clinical experience shifted mid-pandemic toward high-flow oxygen therapy as the higher-volume need, with mechanical ventilation reserved for the most severe cases. That shift left two separate, compounding constraints: the production/allocation problem this edition tracks (chips), and a distinct, longer-running infrastructure and absorption-capacity problem (medical-grade oxygen delivery, PSA plants, trained biomedical staff) that predates and outlasts any single chip cycle. This edition addresses the first; the absorption-capacity of end-users problem is the subject of the planned follow-on edition.
The 2021–23 ventilator overcorrection, for context
The initial demand shock led to very large national ventilator orders placed under uncertainty. A portion of that capacity was never needed at the volumes expected, producing multi-year surplus stockpiles and, in at least one documented case, the sale of ventilator components as scrap metal years after procurement. This is the closest available analogue for what a repeated over-/under-correction cycle could look like if oxygen-equipment allocation follows the same path.
Sub-tier and shared-infrastructure exposure
Most manufacturers have visibility only into their direct (tier-1) suppliers, with no reliable way to proactively identify instability within sub-tiers or cross-sectorally. Named oxygen-equipment manufacturers' public disclosures address their own supply resilience, but no source located in this research pass describes comparable resilience at the smaller specialty component suppliers feeding into PSA-plant and concentrator production, a gap in available sources, not a finding that such resilience is absent.